Moving toward uniform and evidence-based practice of radiotherapy for management of cervical cancer in Ontario, Canada.

PURPOSE: To recognize the practice of radiotherapy for management of cervical cancer in Ontario, Canada, and to use the results of the survey to harmonize and standardize practice across the province. METHODS AND MATERIALS: An electronic survey (SurveyMonkey) was sent to all 14 provincial cancer centers by Cancer Care Ontario Gynecology Community of Practice (CoP) in 2013. The survey included 72 questions in four different categories: general/demographic, pretreatment assessment, external beam radiotherapy (EBRT), and brachytherapy (BT). RESULTS: Ten of 14 centers treated cervical cancer patients and had a dedicated BT suite. All 10 centers had a peer review process for quality assurance. EBRT technique was a 4-field box in eight of 10 centers. The dose/fractionation for pelvic EBRT was 45-50 Gy in 1.8-2 Gy/fraction in all but one center. Nine of 10 centers used high-dose-rate BT. Only one center offered interstitial BT. For treatment planning, two centers used CT and MRI, five centers used CT, and three centers used orthogonal x-rays. Groupe Européen de Curiethérapie and the European Society for Radiotherapy & Oncology guidelines were used in four of seven of the centers for target volume delineation and in five of seven centers for organs at risk dose constraints. All but one center prescribed and reported dose to Point A. CONCLUSIONS: The survey identified areas where practice varied across the province. Gynecology CoP used this information to identify priorities for practice change and implemented several strategies to harmonize the care of women with cervical cancer. This highlights the value of interdisciplinary, grass-roots initiatives such as CoPs to standardize practice in a practical manner that directly benefits patients.

Examination of Jeltrate Plus as a tissue equivalent bolus material.

A product available commercially for making dental impressions, Jeltrate Plus, was evaluated as a tissue equivalent bolus material. Jeltrate Plus was found to be tissue equivalent in 6 and 15 MV photon energy beams and 6, 12, and 20 MeV electron energy beams. As a first step, different preparations for making the bolus material were investigated and an optimal mixture was determined to be two parts Jeltrate Plus powder to three parts water by weight. A suitable method for storing the material was found to be in a water filled plastic container. Since the product is fairly inexpensive and is easily and quickly made and moulded into different shapes, it is an excellent bolus material to use when treating irregular patient contours.